US and Japanese patents cover the Company’s whole slide imaging and analysis platform, which simultaneously measures tumor, immune, and stromal cells, processes, and biomarkers on a single specimen
PITTSBURGH, Pa. – Cernostics, a diagnostics company delivering next generation cancer diagnostics through a unique approach to tissue analysis, announced today that the United States Patent and Trademark Office has issued two patents, US Patent 8,114,615 and US Patent 8,597,899, covering different aspects of its proprietary TissueCypher™ Technology Platform. A third patent was issued by the Japanese Patent Office, Patent 5406019, also related to the TissueCypher™ Technology Platform.
Most current diagnostic approaches offer a limited view of cancer, because they fail to evaluate the tumor as a system composed of multiple, interacting cell types, not merely tumor cells. Cernostics’ patented technology is based on a tissue systems biology approach to anatomic pathology, simultaneously evaluating tumor, immune, and stromal cells, processes, and biomarkers on a single slide, while preserving and evaluating tissue structure.
From a tissue section mounted on a single slide, the TissueCypher™ platform identifies:
- Tissue structure (morphology)
- Specific cell types within the tissue such as immune, epithelial, and stromal cell types
- Biomarker intensity and co-expression patterns
- Spatial relationships, including distributions and gradients of biomarker expression within tissue structures and cell types
“These patents are an important part of our intellectual property strategy and provide our technology platform with long-term market exclusivity,” said Mike Hoerres, Chief Executive Officer of Cernostics. “No other diagnostics technology can replicate our tissue systems biology approach to anatomic pathology – the TissueCypher™ platform will bring unique, actionable information to the healthcare community.”
Cernostics is collaborating with top healthcare organizations around the world to bring TissueCypher™ to market, including Geisinger Health System, the University of Pittsburgh, and the University of Pennsylvania. To learn more about Cernostics, its collaborators and its technology, please visit www.cernostics.com.
Cernostics delivers next generation cancer diagnostics and prognostics through an innovative approach to tissue analysis – the evaluation of the tumor as a system composed of multiple interacting cell types, including tumor, immune, and stromal cells. Its patent-protected technology platform, TissueCypher™, uniquely analyzes whole slide digital images with multiplexed fluorescence, and is designed to provide greater information and accuracy than traditional tissue diagnostics. Cernostics’ lead product, TissueCypher™ Barrett’s Esophagus Assay, will deliver the most comprehensive evaluation of esophageal cancer risk for Barrett’s Esophagus patients currently available, providing actionable information to gastroenterologists and pathologists. For more information, visit www.cernostics.com.
Originally published February 11, 2014